Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05818852 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT05818852 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 72 participants.
The verdict
NCT05818852, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effects of clinical and high clinical exposures of VX-548 and its metabolite on QTcF, and the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-548 and its metabolite.
Interventions
- DRUG Moxifloxacin
- DRUG Moxifloxacin Placebo
- DRUG VX-548
- DRUG VX-548 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2023-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05818852
The ClinicalTrials.gov registry entry for NCT05818852 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT05818852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05818852 about?
NCT05818852 is a clinical study titled "A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants". The purpose of the study is to evaluate the effects of clinical and high clinical exposures of VX-548 and its metabolite on QTcF, and the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-548 and its metabolite.
What is the current status of trial NCT05818852?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2023-04-12. Estimated completion is 2023-06-28.
What interventions are being tested in trial NCT05818852?
The interventions under investigation include: Moxifloxacin (DRUG), Moxifloxacin Placebo (DRUG), VX-548 (DRUG), VX-548 Placebo (DRUG).
Who is sponsoring clinical trial NCT05818852?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.